Literature DB >> 18538110

Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China.

Y-T Xiang1, Y-Z Weng, C-M Leung, W-K Tang, G S Ungvari.   

Abstract

BACKGROUND: To date, no study has investigated the use of depot antipsychotic medication (DA) in Chinese outpatients with schizophrenia. This study explored the frequency and sociodemographic and clinical correlates of DA in schizophrenia outpatients in both Hong Kong (HK) and Beijing (BJ), China.
METHODS: 505 clinically stable outpatients with schizophrenia were randomly selected and interviewed in HK and BJ using standardized assessment instruments. Their basic sociodemographic and clinical data and psychotropic drug prescriptions were collected at the time of a diagnostic interview.
RESULTS: 117 (23.2%) patients were prescribed DA, 36.1 and 10% of the HK and BJ samples, respectively. Prescription of DA was associated with a history of suicide, less use of clozapine, more frequent antipsychotic polypharmacy (APP), more frequent admissions, and study site (HK vs. BJ). In multiple logistic regression analysis, study site, less frequent prescription of clozapine, history of suicide, and more frequent use of APP remained significantly associated with DA.
CONCLUSION: There was wide variation in the frequency of DA prescribing between HK and BJ even though the ethnic and clinical characteristics of the two samples were nearly identical. This suggests that sociocultural and economic factors, as well as traditions in psychiatric training and practice all played a role in determining the use of DA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538110     DOI: 10.5414/cpp46245

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  8 in total

Review 1.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

2.  Evaluation of Defined Daily Dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization.

Authors:  Waleed M Sweileh; Jihad Bani Odeh; Naser Y Shraim; Sa'ed H Zyoud; Ansam F Sawalha; Samah W Al-Jabi
Journal:  Saudi Pharm J       Date:  2013-04-06       Impact factor: 4.330

3.  Dose Equivalents for Antipsychotic Drugs: The DDD Method.

Authors:  Stefan Leucht; Myrto Samara; Stephan Heres; John M Davis
Journal:  Schizophr Bull       Date:  2016-07       Impact factor: 9.306

Review 4.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

5.  Prevalence of metabolic syndrome among patients with schizophrenia in Palestine.

Authors:  Waleed M Sweileh; Sa'ed H Zyoud; Salah A Dalal; Sami Ibwini; Ansam F Sawalha; Iyad Ali
Journal:  BMC Psychiatry       Date:  2012-12-27       Impact factor: 3.630

6.  Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics.

Authors:  Ludovic Samalin; Marion Garnier; Candy Auclair; Pierre-Michel Llorca
Journal:  Int J Mol Sci       Date:  2016-11-19       Impact factor: 5.923

7.  Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy.

Authors:  Waleed M Sweileh; Jihad Bani Odeh; Sa'ed H Zyoud; Ansam F Sawalha; Manal S Ihbeasheh
Journal:  BMC Psychiatry       Date:  2013-07-01       Impact factor: 3.630

8.  Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.

Authors:  Steven Potkin; Rimal Bera; Donna Zubek; Gina Lau
Journal:  BMC Psychiatry       Date:  2013-10-16       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.